Original Article

1

2

3

4

56

7

8

9

15

16

A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and

tolerability of hydroxychloroquine and a retrospective study in adult patients with mild

to moderate Coronavirus disease 2019 (COVID-19)

Running title: Hydroxychloroquine for COVID-19

Authors

- 10 Cheng-Pin Chen^{1,2¶}, Yi-Chun Lin^{1,3¶}, Tsung-Chia Chen⁴, Ting-Yu Tseng⁴, Hon-Lai Wong⁵,
- 11 Cheng-Yu Kuo⁶, Wu-Pu Lin⁷, Sz-Rung Huang⁸, Wei-Yao Wang⁹, Jia-Hung Liao¹⁰, Chung-
- 12 Shin Liao¹¹, Yuan-Pin Hung¹², Tse-Hung Lin¹³, Tz-Yan Chang¹³, Chin-Fu Hsiao¹⁴, Yi-Wen
- Huang^{13,15&}, Wei-Sheng Chung^{4,16,17&}, Chien-Yu Cheng^{1,18&}, Shu-Hsing Cheng^{1,19&}, on behalf
- of the Taiwan HCQ Study Group^

Affiliations

- 1. Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and
- 18 Welfare, Taoyuan, Taiwan
- 19 2. Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
- 20 3. Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan
- 21 4. Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare,
- Taichung, Taiwan
- 23 5. Department of Internal Medicine, Keelung Hospital, Ministry of Health and Welfare,
- 24 Keelung City, Taiwan
- 25 6. Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare,
- Pingtung, Taiwan
- 27 7. Department of Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New
- 28 Taipei City, Taiwan
- 29 8. Department of Internal Medicine, Miaoli General Hospital, Ministry of Health and
- Welfare, Miaoli, Taiwan
- 31 9. Department of Internal Medicine, Feng Yuan Hospital, Ministry of Health and Welfare,
- 32 Taichung, Taiwan
- 33 10. Department of Internal Medicine, Nantou Hospital, Ministry of Health and Welfare,
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

 Nantou, Taiwan

- 35 11. Department of Internal Medicine, Chia Yi Hospital, Ministry of Health and Welfare,
- 36 Chiayi, Taiwan
- 37 12. Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare,
- 38 Tainan City, Taiwan
- 39 13. Department of Internal Medicine, Chang Hua Hospital, Ministry of Health and Welfare,
- 40 Changhua, Taiwan
- 41 14. Institute of Population Health Sciences, National Health Research Institutes, Zhunan,
- 42 Taiwan
- 43 15. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
- 44 16. Department of Health Service Administration, China Medical University, Taichung,
- 45 Taiwan

59

60

- 46 17. Department of Healthcare Administration, Central Taiwan University of Science and
- 47 Technology, Taichung, Taiwan
- 48 18. School of Public Health, National Yang-Ming University, Taipei, Taiwan
- 49 19. School of Public Health, Taipei Medical University, Taipei, Taiwan
- 51 **These authors had equal contribution to the study.
- 52 Alternative corresponding author: Yi-Wen Huang, email:hiwen@gmail.com; Wei-Sheng
- Chung, email: chung.w53@msa.hinet.net; Chien-Yu Cheng, email: vajien@mail.tygh.gov.tw
- Corresponding author: Shu-Hsing Cheng, email: shcheng@mail.tygh.gov.tw
- 55 1492 Jhongshan Rd. Taoyuan Dist., Taoyuan City 33004, Taiwan
- 56 Tel: 886-3-3699721
- 57 Fax: 886-3-3789127
- 58 ^Full authorships are listed in the Acknowledgements section.

Abstract

Objective

61

62

- In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus
- disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study.

65 Methods

- Subjects admitted to 11 designated public hospitals in Taiwan between April 1 and May 31,
- 67 2020, with COVID-19 diagnosis confirmed by pharyngeal real-time RT-PCR for SARS-CoV-
- 2, were randomized at a 2:1 ratio and stratified by mild or moderate illness. HCQ 400 mg
- 69 twice for 1 d and HCQ 200 mg twice daily for 6 days were administered. Both study group
- and controlled group received standard of care (SOC). Pharyngeal swabs and sputum were
- 71 collected every other day. The proportion and time to negative viral PCR were assessed on
- day 14. In the retrospective study, medical records were reviewed for patients admitted before
- 73 March 31, 2020.

74 **Results**

- 75 There were 33 and 37 cases in the RCT and retrospective study, respectively. In the RCT, the
- median times to negative rRT-PCR from randomization to hospital day 14 were 5 days (95%)
- CI; 1–9 days) and 10 days (95% CI; 2–12 days) for the HCQ and SOC groups, respectively (p
- 78 = 0.40). On day 14, 81.0% (17/21) and 75.0% (9/12) of the subjects in the HCQ and SOC
- groups, respectively, had undetected virus (p = 0.36). In the retrospective study, 12 (42.9%) in
- the HCQ group and 5 (55.6%) in the control group had negative rRT-PCR results on hospital
- 81 day 14 (p = 0.70).

Conclusions

- 83 Neither study demonstrated that HCQ shortened viral shedding in mild to moderate COVID-
- 84 19 subjects.

82

85

87

86 Keywords: COVID-19; SARS-CoV-2; rRT-PCR; randomized control trial; area under curve

Introduction

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is an ongoing pandemic. The outbreak was first localized to Wuhan, Hubei Province, People's Republic of China (PRC) on December 31, 2019 [1]. On January 30, 2020, the World Health Organization (WHO) declared that the outbreak was a public health emergency of international concern and thereafter recognized it as a pandemic [2,3]. As of June 20, 2020, more than eight million cases of COVID-19 have been reported in 187 countries and territories. More than 450,000 deaths have been associated with this infection [4]. Taiwan is a close neighbor of PRC and reported its first COVID-19 case on January 21, 2020 [5]. As of June 20, 2020, there were 446 confirmed COVID-19 cases in Taiwan. As a result of the early implementation of social distancing, hand hygiene, and face masks, Taiwan has had a low incidence of domestic COVID-19 cases [6]. There is no known effective medical treatment against COVID-19. The mechanisms of potentially efficacious antiviral agents include the inhibition of RNA-dependent RNA polymerase (remdesivir [7-9] and favipiravir [10]), protease inhibition (lopinavir/ritonavir [9, 11, 12] and ivermectin [13]), the blockade of virus-cell membrane fusion (recombinant human angiotensin-converting enzyme 2 [14] and chloroquine and hydroxychloroquine (HCQ) [8,15], and the modulation of the human immune system (interferon [9] and interleukin-6 blockers [16,17]). Chloroquine phosphate is a well-known antimalarial drug that has been on the market for several decades. An *in vitro* study showed that chloroquine is effective against SARS-CoV-2 at the entry and post-entry infection stages [8]. Chloroquine may either increase endosomal pH by blocking the fusion of the virus and the host cell membrane [18] or by interfering with cell receptor glycosylation [19]. Chloroquine may also repress proinflammatory signaling and cytokine (IL-1, IL-6, and TNF) production by inhibiting lysosome activity in antigenpresenting cells [20]. Compared to chloroquine, HCQ has an additional hydroxyl group, lower toxicity, and similar antiviral efficacy. HCO received emergency approval by the US Food and Drug Administration (FDA) for used in the treatment of COVID-19 [21]. However, the efficacy of HCQ against SARS-CoV-2 has

been highly controversial. Certain elite journals have retracted influential papers published on the efficacy of HCQ against COVID-19 [22, 23]. HCQ is widely available in Taiwan and has become the potential candidate drug therapy against COVID-19 there. In addition to performing a retrospective observational study, the people of Taiwan were privileged to undergo a randomized clinical trial) as every confirmed COVID-19 case should be quarantined and treated in hospital until viral shedding has ceased. So, an open-label RCT involving multiple centers were conducted to evaluate HCQ efficacy and tolerability in adult patients with mild to moderate COVID-19. Comparison would be made with the standard of care treatment (SOC) in Taiwan.

Methods

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

Clinical trial

Participants The clinical trial was conducted at 11 public hospitals in northern, central, and southern Taiwan affiliated with the Ministry of Health and Welfare, Taiwan, between April 1 and May 31, 2020. Enrolled patients were aged 20–79 y and confirmed positive for SARS-CoV-2 infection by real-time reverse transcription polymerase chain reaction (rRT-PCR). They provided signed informed consent. Upon admission, the patients were stratified into three groups: (1) mild illness without evidence of infiltration according to chest roentgenography; (2) moderate illness with evidence of infiltration according to chest roentgenography but neither respiratory distress nor supplemental oxygen requirement; and (3) severe illness with respiratory distress, oxygen supplementation, and evidence of infiltration according to chest roentgenography. Participants presenting with severe illness were excluded from this study. The following patients were excluded from the trial: (a) documented history of hypersensitivity to quinine derivatives; (b) retinal disease; (c) hearing loss; (d) severe neurological or mental illness; (e) pancreatitis; (f) lung disease; (g) liver disease (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) $> 3 \times$ the normal upper limit); (h) kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m² according to MDRD or CKD-EPI); (i) hematological disease; (j) cardiac conduction abnormalities at electrocardiographic (ECG) screening with long OT syndrome or OTcF interval > 450 msec for males and > 470 msec for females according to Fridericia's correction at screening; (k) known HIV infection; (1) active hepatitis B or C without concurrent treatment (positive for hepatitis B [HBsAg and HBeAg] or hepatitis C ribonucleic acid [RNA] titer > 800,000 IU/mL); (m) G6PD; (n) psychiatric disorders and alcohol/substance dependence/abuse that may jeopardize patient safety; and (o) pregnant or breast-feeding women.

Clinical course

- 160 COVID-19 symptoms were recorded and followed up daily. Chest X-rays,
- electrocardiography, and the biomarkers complete blood count, white blood cell differential
- 162 count, biochemistry, prothrombin time, activated partial thromboplastin time, ferritin, highly

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

active troponin I, C-reactive protein, and erythrocyte sedimentation rate were tested upon admission and every 4 days after enrollment. **PCR** assay Nasopharyngeal swab and sputum were collected every other day until patient discharge following three consecutive negative results or day 14 of the study, depending upon which criterion was met first. SARS-CoV-2 RNA was assessed by rRT-PCR using a hydrolysis probe-based system targeting genes encoding envelope (E) protein and RNA-dependent RNA polymerase (R) as previously described [24]. Negative viral RNA detection was defined as cycle thresholds (Ct) values > 38 for the E gene and negative for the R gene. The PCR assay was conducted at the National Laboratory of the Taiwan Centers for Disease Control. Study design Eligible subjects were randomly assigned by an interactive web response system in a 2:1 ratio to receive either HCQ plus standard of care (SOC) or SOC alone. They were stratified by mild or moderate illnesses within 4 days of diagnosis. The incidence of domestic cases was low and the estimated case ratio was 30:15. The HCQ administration plan was 400 mg b.i.d. on day 1 and 200 mg b.i.d. for 6 days on days 2–7. Both study group and comparison group received standard of care comprising supportive treatment for subjects with mild clinical COVID-19 symptoms and antimicrobial therapy for subjects presenting with moderate clinical COVID-19 symptoms. The treatment consisted of: (1) ceftriaxone 2 g daily for 7 days ± azithromycin 500 mg on day 1 and 250 mg on days 2–5; or (2) levofloxacin 750 mg daily for 5 d; or (3) levofloxacin 500 mg daily; or (4) moxifloxacin 400 mg daily for 7–14 days for subjects allergic to ceftriaxone or azithromycin or according to physician discretion. Oseltamivir 75 mg b.i.d. will be administered for 5 days to subjects presenting with concomitant influenza A or B infection. No HCQ dose reduction, modification, or change in administration frequency will be recommended during the study period. The clinical trial registry number is NCT04384380. **Outcome measurement** The primary endpoint was to evaluate the efficacy of HCQ with respect to time to negative rRT-PCR assessments from randomization up to 14 days. The secondary endpoints were to evaluate the proportion of negative viral rRT-PCR on hospital day 14, the resolution of

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

clinical symptoms (time to clinical recovery), the proportion of discharges by day 14, and the mortality rate. HCQ safety and tolerability were also evaluated. Statistical analysis Data were entered into an electronic clinical trial information management system (CTIMeS; National Health Research Institutes, Taiwan) by study coordinators and summarized with SAS® v. 9.2 (SAS Institute Inc., Carv. NC, USA) All treatment data will be summarized using descriptive statistics including continuous variables (number of non-missing observations, means, standard deviations (SD), medians, minima, and maxima), categorical variables (frequencies and percentages), and time to event variables (number of non-missing observations (N), medians, minima, and maxima). The negative rRT-PCR rates between treatment and control arms were compared by using fisher exact test and Cochran-Mantel-Haenszel (CMH) test, stratified with mild or moderate illnesses. Kaplan-Meier method was used to estimate the distribution of time to negatively rRT-PCR. The median of time to negatively rRT-PCR and its 95% CI were provided. The log-rank test with/without adjustment by disease severity was used to compare the distribution of time to negatively rRT-PCR between two arms. The Analysis of Covariance (ANCOVA) adjusted for mild/moderate diseases) was performed to compare the AUC between two arms. All tests were two-tailed. A P value <0.05 was considered significant. **Ethical statement** The study protocol was approved by the Institutional Review Board of Taoyuan General Hospital (IRB No. TYGH109014). The study was performed according to Good Clinical Practices recommended by the Declaration of Helsinki and its amendments. Retrospective observational study The study was conducted at aforementioned hospitals. Cases were aged 20–79 y and confirmed positive for SARS-CoV-2 infection by rRT-PCR between January 25 and March 31, 2020. Medical registers were reviewed and clinical symptoms, laboratory data, and medications were recorded. Patients who had undetected virus within 2-days of hospitalization were excluded. The study protocol was approved by the Institutional Review Board of Taoyuan General Hospital (IRB No. TYGH109024).

Results

229

230

231

237

238

239

241

242

Clinical trial

- Thirty-three cases were enrolled in the RCT (Fig. 1). The mean age (SD) of the subjects was
- 32.9 (10.7) y. Males comprised 57.6% of all subjects. A few individuals presented with
- underlying chronic illnesses. The initial presentation included anosmia (51.5%), cough
- 235 (48.5%), ageusia (30.0%), nasal obstruction (24.2%), and sore throat (21.2%). Of these,
- 236 12.1% of the cases had pneumonia according to the X-ray images (Table 1).

Fig 1. Patient disposition in the multicenter, open-label, randomized controlled trial (a)

- and the retrospective study (b) of hydroxychloroquine.
- 240 Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care

Table 1. Baseline demographic and clinical characteristics of participants in the multi-center,

open-label, randomized clinical trial and the retrospective observational study.

	Randomized controlled trial					
	HCQ		SC	OC		Overall
No. randomized patients	21		12		33	
Mean age (Std)	33.0	(12.0)	32.8	(8.3)	32.9	(10.7)
Median (range)	30.0	(22-68)	33.5	(22-44)	31.0	(22-68)
Male (%)	11	(52.4%)	8	(66.7%)	19	(57.6%)
Stratification						
Mild (%)	19	(90.5%)	10	(83.3%)	29	(87.9%)
Moderate (%)	2	(9.5%)	2	(16.7%)	4	(12.1%)
Symptoms						
Median of QTc msec (range)	424	(356-453)	427.5	(392-458)	424	(356-458)
Anosmia (%)	11	(52.4%)	6	(50%)	17	(51.5%)
Cough (%)	9	(42.9%)	7	(63.6%)	16	(48.5%)
Ageusia (%)	4	(19.0%)	6	(50%)	10	(30.3%)
Nasal obstruction (%)	4	(19.0%)	4	(33.3%)	8	(24.2%)

Sore throat (%)	3	(14.3%)	4	(33.3%)	7	(21.2%)	
Shortness of breath (%)	1	(4.8%)	1	(8.3%)	2	(6.1%)	
Fever (%)	1	(4.8%)	0	(0%)	1	(3.0%)	
	Retrospective observational study						
	HCQ Control				Total		
No. patients	28		9		37		
Mean age (Std)	34.3	(14.5)	31.3	(18.0)	35.8	(14.5)	
Median (range)	28	(20-66)	44	(21-56)	29	(20-66)	
Male (%)	14	(50%)	3	(33.3%)	17	(45.9%)	
Stratification							
Mild (%)	23	(82.1%)	6	(66.7%)	29	(78.4%)	
Moderate (%)	5	(17.9%)	3	(33.3%)	8	(21.6%)	
Symptoms	28		9		37		
Median of QTc msec (range)	NA		NA		NA		
Anosmia (%)	8	(28.6%)	1	(11.1%)	9	(24.3%)	
Cough (%)	18	(64.3%)	3	(33.3%)	21	(56.8%)	
Ageusia (%)	5	(17.9%)	1	(11.1%)	6	(16.2%)	
Sore throat (%)	8	(28.6%)	2	(22.2%)	10	(27.0%)	
Shortness of breath (%)	0	(0%)	1	(11.1%)	1	(2.7%)	
Fever (%)	15	(53.6%)	3	(33.3%)	18	(48.6%)	

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; NA: not available 245

Twenty-one cases were randomized to the HCQ group and 12 cases were randomized to the 246 SOC group. However, two in the HCQ group and one in the SOC group had withdrawn 247 consents before the first dose was administered. One (4.8%) in the HCQ group and two 248 (16.7%) in the SOC group were concomitantly administered azithromycin. 249 250 The median times to negative rRT-PCR assessment from randomization to hospital day 14 were 5 days (95% CI; 1–9 days) for the HCQ group and 10 days (95% CI; 2–12 days) for the 251 SOC group (p = 0.40) (Fig. 2; Table 2). By day 14, 81.0% (17/21) and 75.0% (9/12) of the 252 subjects in the HCQ and SOC groups, respectively, had undetected virus (p = 0.36) (Table 2). 253 Analysis of area under curve of Ct value in the study interval showed that least square mean 254 (SD) were 501.7 (18.0) for HCQ group and 496.6 (21.2) for SOC group. The treatment 255 difference (95% CI) was 5.1 (-37.1 –47.2) (p=0.81) (Table 3). For subjects presenting with 256 257 mild illness, the median times to negative rRT-PCR assessment from randomization were 5 258 days (95% CI; 1–11 days) for the HCQ group and 11 days (95% CI; 1–12 days) for the SOC 259 group (p = 0.31) (Supplemental Fig. 3; Table 4).

Fig. 2. Probabilities of non-negative responses vs. time (days) for subjects in the HCQ and SOC groups in the multicenter, open-label, randomized controlled trial.

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care

260

261

262

263

264

265

266

267

268

269

270

271272

273274

275

276

277

278

Table 2. Proportions of negative rRT-PCR assessments on day 14 and median times to negative rRT-PCR results after randomization in the multicenter, open-label, randomized controlled trial.

			P-value*1	Median time to negative [#]	P-value*2
Group	N	Negative*		(Days, 95% CI)	
HCQ	21	17 (81.0%)	0.71	5 (1,9)	0.40
SOC	12	9 (75.0%)		10 (2,12)	

Abbreviations: HCQ: hydroxychloroquine; SOC: standard of care; CI: confidence interval;

By day 14, 28.6% of the subjects in the HCQ group and 41.7% of the subjects in the SOC group presented with clinical recovery (p = 0.51) (Supplemental Fig. 4; Table 5). By day 14, 19.0% and 16.7% of the subjects in HCQ group and SOC group, respectively, were off-quarantined. There was no mortality in the present study.

^{*}Negative event: both pharyngeal swab and sputum showed negative results; *Time to negative = Event date or censored date – start day

^{*1} CMH test: stratified by clinical syndromes; *2 Log-rank test stratified by clinical syndromes

No severe adverse events were reported in the clinical trial. Grades 1 and 2 HCQ-related adverse events included headache (21.1%), dizziness (5.3%), gastritis (5.3%), diarrhea (5.3%), nausea (5.3%), and photophobia (5.3%). The median QTc (ranges) were 429.5 msec (340–467) on day 4 and 421 msec (391–462) on day 8. No severe prolongation was noted. **Retrospective observational study**Thirty-seven cases were enrolled in the observational study (Fig. 1). The mean age (SD) of the subjects was 35.8 (14.5) y. There were 17 (45.9%) male subjects. Twenty-three (82.1%) in the HCQ group and zero (0%) in the control group were administered azithromycin concomitantly.

The median times (ranges) to undetected virus were 15 (6–31) days for the HCQ group and 14 (7–22) days for the control group (p = 0.37) (Supplemental Table 2.1). On hospital day 14, the airway samples of 12 subjects (42.9%) in the HCQ group and 5 subjects (55.6%) in the control group turned negative rRT-PCR results (p = 0.70). On hospital day 14, the mean log change (SD) of Ct value was 7.6 (4.8) in HCQ group and 11.6 (5.6) in control group, respectively (p = 0.0625).

Discussion

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

The present multicenter, randomized, open-label clinical trial showed that HCQ failed the primary endpoint of shortening the viral clearance interval. The retrospective study also demonstrated that HCO conferred no therapeutic benefit to the COVID-19 cases investigated here. Currently, there are > 1,000 ongoing COVID-19 clinical trials worldwide. In multicenter clinical trials conducted in China, chloroquine phosphate demonstrated efficacy at preventing the progression of COVID-19-related pneumonia [25]. The Chinese guideline [26] recommended for adults aged 18–65 y is 500 mg twice daily for 7 days in patients weighing > 50 kg and 500 mg twice daily for 2 days followed by 500 mg once daily for 5 days in patients weighing < 50 kg. A clinical trial in Italy was planned to include 440 patients and test two different chloroquine doses but was suspended after 81 patients had been enrolled because of excessive OTc prolongation and high mortality rates in the high-dose (600 mg twice daily for 10 days) group [27]. Compared to the study of Borba et al. [27], the participants in our clinical trial were younger, did not receive high HCQ doses, and presented with a low incidence of QTc prolongation. The first open-label, non-randomized study of HCQ treatment for COVID-19 was conducted in France [15]. Gautret et al. treated 20 patients with 200 mg HCQ thrice daily for 10 days. Six of these patients were administered concomitant azithromycin and 16 other patients received no HCQ therapy. The efficacy of HCQ at clearing the virus was remarkable: 70.0% by day 6 post-inclusion in treated patients vs. 12.5% at day 6 post-inclusion in untreated patients (p < 0.001). However, six of the patients being administered HCQ became clinically worse or were lost to follow-up. Consequently, they were excluded from the final analysis and interpretation of the data became very difficult. Hence, the same team performed an uncontrolled non-comparative observational study on a cohort comprising 80 patients presenting with mild COVID-19 symptoms who underwent HCQ and azithromycin treatment [28]. Subsequently, rapid declines in nasopharyngeal viral load were reported (83% and 93%) of the treated patients at days 7 and 8, respectively). A large-scale observational study was conducted on 1,376 COVID-19 patients in New York [29] of whom 58.9% were administered HCQ 600 mg twice on day 1 and 400 mg daily thereafter for a median of 5 days. However,

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

HCQ administration was not associated with the composite intubation or death endpoint (hazard ratio = 1.04; 95% CI = 0.82-1.32). A pilot randomized controlled clinical trial (No. NCT04261517) on HCQ therapy for COVID-19 was performed at a single center in Shanghai. It enrolled 30 patients with 1:1 randomization [30]. The study did not reveal any significant difference between the two treatment groups. The viral clearance rates in the throat swab samples were relatively high by day 7 after enrolment in both groups (83.7% vs. 96.3%, respectively; p > 0.05). Moreover, the HCQ dose was comparatively low and the treatment interval was relatively short (400 mg daily for 5 days; no loading). All patients in this trial received aerosolized interferon alpha and most of them were also administered antiviral drugs that may have diminished or augmented the therapeutic efficacy of HCQ. Another clinical trial (No. ChiCTR2000029559) enrolled 62 subjects of whom 31 received HCO 400 mg/d for 5 days. The remaining 31 constituted the control group [31]. After 5 days, the clinical recovery time of the HCQ group was significantly shortened and fever and cough were alleviated relatively faster (p < 0.05). Pneumonia improved in 81% of the subjects in the HCQ group and in 55% of the patients in the control group (p < 0.05). Although this study corroborated the therapeutic efficacy of HCQ, it did not measure or report viral clearance rates. A recent multicenter, randomized, open-label clinical trial was conducted at 16 COVID-19 treatment centers in China and disclosed negative conversion rates of 85.4% and 81.3% for SARS-CoV-2 28 days after randomization into HCQ + SOC and SOC groups, respectively [32]. In Tang's study, 98.6% (148/150) of the enrolled subjects were categorized as presenting with mild to moderate illness but 63% of the enrollees had also been treated with antiviral agents (arbidol, virazole, lopinavir/ritonavir, oseltamivir, or entecavir) which may have interfered with HCQ efficacy. The strength of our RCT lies in the fact that the enrollees were randomized within 4 days of diagnosis. Thus, the earliest possible intervention could be made. Clinical courses could be clearly and accurately monitored because of early diagnosis and treatment with SOC or HCQ. Furthermore, the HCO treatment regimen used here consisted of loading twice with 400 mg followed by 200 mg twice daily for 7 days [33]. A physiologically based pharmacokinetic

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

model indicated that the aforementioned dose used in the present study was ideal for HCQ therapy [34]. Third, no antiviral therapy was given, and only 1 case in the HCQ group and 2 cases in the SOC group had azithromycin treatment. In contrast, there were limitations to the present study. Only patients presenting with mild to moderate disease symptoms were enrolled in order to determine the viral clearance efficacy of HCQ. Hence, there is relatively little data on the impact of severe disease in terms of intubation and mortality. At clinical trial launch, there were no indigenous and very few imported cases in Taiwan. Therefore, study enrollment was prematurely stopped. The low case numbers in the present study might account for the apparent lack of superior efficacy of HCQ. However, 81% of the HCQ group and 75% of the SOC group had confirmed viral clearance on hospital day 14. Moreover, according to Taiwan CDC regulations, subjects could not be off-quarantine until they presented with at least three consecutive negative rRT-PCR results. The outcome of this RCT may assist the Taiwan CDC in their decision to release quarantined patients when medical resources are in short supply. Another limitation of the study was that the mean patient age (SD) was 32.9 (10.7) y as opposed to 51.1 y (13.9) for Borba et al., 45.1 y for Gautret et al., 44.7 y (15.3) for Chen et al., and 46.1 y (14.7) for Tang et al. [15,27,31,32]. For this reason, the observed rates of cardiac and retinal toxicity were low in the present study. Electrocardiogram monitoring was performed frequently and close attention was paid to any changes in patient QTc interval, vision, and neurological symptoms. Lastly, readers might question about the gap in median time to negative viral detection between retrospective observational study and RCT. Since the date of HCQ initiation was very diverse, and the frequency of viral sampling was not the same in the retrospective observational cohort, the different outcome comparing to RCT was not surprised. **Conclusions** Both the retrospective and randomized clinical studies performed here failed to demonstrate HCQ efficacy at shortening viral shedding in subjects presenting with mild to moderate COVID-19 symptoms. Future research should conduct large-scale studies involving more patients to investigate new agents or combinational therapy, and explore the viral dynamics.

Acknowledgements The authors thank the Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare for their research grant. This funding source played no role in study design or conduction, data collection, analysis or interpretation, writing of the manuscript, or decision to submit it for publication. The authors also thank Taiwan Biotech Co. Ltd. for their donation of investigational products, the National Health Research Institutes, Taiwan Centers for Disease Control, Taiwan Food and Drug Administration, Center for Drug Evaluation, Taiwan for their technical assistance, and all study members participating in the Taiwan HCQ Study Group led by Shu-Hsing Cheng (shcheng@mail.tygh.gov.tw), namely, Chien-Yu Cheng*, Yi-Chun Lin*, Cheng-Pin Chen*, and Shu-Hsing Cheng* from Taoyuan General Hospital, Ministry of Health and Welfare, Chin-Feng Lin, Jiing-Chyuan Luo, Fu-Shun Tsai, Tsung-Yen Yang, Wen-Chen Yau, and Hon-Lai Wong* from Keelung Hospital. Ministry of Health and Welfare, Wu-Pu Lin*, Lin-Chen Chien, Chen-Han Yiu, Chien-Yu Huang, and Yung-Tsung Hsiao from Taipei Hospital, Ministry of Health and Welfare, Ming-Huei Lee and Sz-Rung Huang* from Miaoli General Hospital, Ministry of Health and Welfare, Wei-Sheng Chung*, Tsung-Chia Chen*, and Ting-Yu Tseng* from Taichung Hospital, Ministry of Health and Welfare, Wei-Yao Wang*, Yih-Farng Liou, and Chen-Feng Chiu from Feng Yuan Hospital, Ministry of Health and Welfare, Yi-Wen Huang*, Yang-Hao Yu, Tse-Hung Lin*, and Tz-Yan Chang* from Chang Hua Hospital, Ministry of Health and Welfare, Hung-Chang Hung, Tzung-Fan Chuang, Jia-Hung Liao*, Li-Yueh Yeh, and Shu-Ming Huang from Nantou Hospital, Ministry of Health and Welfare, Yuan-Der Huang, Shih-Tien Chen, Chi-Min Shin, and Chung-Shin Liao* from Chia Yi Hospital, Ministry of Health and Welfare, Yuan-Pin Hung*, Chih-I Lee, and Chun-Wei Chiu from Tainan Hospital, Ministry of Health and Welfare, and Shah-Hwa Chou, Cheng-Yu Kuo*, Tz-Lun Hung, and Hsin-Hui Wang from Pingtung Hospital, Ministry of Health and Welfare, and Chin-Fu Hsiao from Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. *Authorships.

Conflict of interest: none

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

References

429

430

- 1. World Health Organization. Naming the coronavirus disease (COVID-19) and the viral
- that caused it, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
- guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it [accessed 20]
- 434 June 2020].
- 435 2. World Health Organization. Statement on the second meeting or the International Health
- Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus
- 437 (2019-nCoV), https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-
- 438 meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-
- outbreak-of-novel-coronavirus-(2019-ncov) [accessed 20 June 2020].
- 440 3. World Health Organization. WHO director-general's opening remarks at the media
- briefing on COVID-19, https://www.who.int/dg/speeches/detail/who-director-general-s-
- opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [accessed 20 June 2020].
- 4. World Health Organization. Novel coronavirus situation report-151. Geneva, Switzerland,
- https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200619-covid-19-
- 445 <u>sitrep-151.pdf?sfvrsn=8b23b56e_2</u> [accessed 20 June 2020].
- 5. Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH et al. First case of
- coronavirus disease 2019 (COVID-19) pneumonia in Taiwan. J Formos Med Assoc.
- 448 2020;119(3):747–51. pii: S0929-6646(20)30044-9.
- https://doi.org/10.1016/j.jfma.2020.02.007. [Epub ahead of print].
- 450 6. Taiwan Centers for Disease Control. CECC confirmed 1 more imported COVID-19
- case; case returns to Taiwan from Bangladesh.
- https://www.cdc.gov.tw/En/Bulletin/Detail/17L0KFRR2KRBn1JygBFPUg?typeid=158[ac
- 453 cessed 20 June 2020].
- 7. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al. First case of
- 455 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):926–32.
- https://doi.org/10.1056/NEJMoa2001191. [Epub ahead of print].
- 8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine
- effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res
- 459 2020;30(3):269–71. https://doi.org/10.1038/s41422-020-0282-0. [Epub ahead of print].
- 9. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ et al. Comparative
- therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon

- beta against MERS-CoV. Nat Commun 2020;11(1):222. https://doi.org/10.1038/s41467-
- 463 019-13940-6.
- 10. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of
- viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93(7):449–63.
- 466 https://doi.org/10.2183/pjab.93.027.
- 11. Cheng CY, Li YL, Chen CP, Lin YC, Liu CE, Liao CH et al. Lopinavir/ritonavir did not
- shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
- J Microbiol Infect Immunol 2020;53(3):488-92 [Web/URL PM:32331982].
- 470 https://doi.org/10.1016/j.jmii.2020.03.032.
- 12. Cao B, Wang Y, Wen W, Liu W, Wang J, Fan G et al. A trial of lopinavir-ritonavir in
- adults hospitalized with severe COVID-19. New Engl J Med 2020;382(19):1787–99.
- 473 Web/URL: PM:32187464. https://doi.org/10.1056/NEJMoa2001282.
- 13. Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug
- ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res
- 476 2020;178:104787. https://doi.org/10.1016/j.antiviral.2020.104787.
- 14. Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M et al. Inhibition of
- SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human
- 479 ACE2. Cell 2020;181(4)905–13. Web/URL: PM:32333836.
- 480 https://doi.org/10.1016/j.cell.2020.04.004.
- 481 15. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al.
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-
- label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
- https://doi.org/10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].
- 16. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
- Antonakos N et al. Complex immune dysregulation in COVID-19 patients with severe
- respiratory failure. Cell Host Microbe 2020;27(6):992–1000. Web/URL: PM:32320677.
- 488 https://doi.org/10.1016/j.chom.2020.04.009.
- 489 17. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-
- inflammatory activities of IL-6. Int J Biol Sci 2012;8(9):1237–47.
- 491 https://doi.org/10.7150/ijbs.4989.
- 492 18. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda RE. Effects of chloroquine on viral
- infections: An old drug against today's diseases. Lancet Infect Dis 2003;3(11):722–27.
- 494 https://doi.org/10.1016/s1473-3099(03)00806-5.
- 495 19. Vincent MJ, Bergeron É, Benjannet S, Erickson BR, Rollin P, Ksiazek TG et al.

- 496 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J
- 497 2005;2:69. https://doi.org/10.1186/1743-422X-2-69.
- 498 20. Zhang Y, Xu Q, Sun Z, Zhou L. Current targeted therapeutics against COVID-19: Based
- on first-line experience in China. Pharmacol Res 2020;157:104854.
- 500 https://doi.org/10.1016/j.phrs.2020.104854.
- 21. U.S. Food and Drug Administration. Reply to request for emergency use authorization for
- use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic
- national stockpile for treatment of 2019 Coronavirus Disease,
- https://www.fda.gov/media/136534/download [accessed 20 June 2020].
- 505 22. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: Cardiovascular disease,
- drug therapy, and mortality in Covid-19. N Engl J Med 2020;NEJMc2021225.
- 507 https://doi.org/10.1056/NEJMoa2007621.
- 508 23. Mehra MR, Ruschitzka F, Patel AN. Retraction—hydroxychloroguine or chloroguine with
- or without a macrolide for treatment of COVID-19: A multinational registry analysis.
- 510 Lancet 2020;395(10240):1820. https://doi.org/10.1016/S0140-6736(20)31324-6.
- 24. World Health Organization. Diagnostic detection of 2019-nCoV by real-time RT-PCR,
- 512 https://www.who.int/docs/ default-source/coronaviruse/protocol-v2-
- 513 1.pdf?sfvrsn=a9ef618c 2 [accessed 20 June 2020].
- 514 25. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent
- efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci
- Trends 2020;14(1):72–3. https://doi.org/10.5582/bst.2020.01047.
- 517 26. National Health Commission of the People's Republic of China. National
- recommendations for diagnosis and treatment of respiratory infections caused by 2019-
- 519 nCoV (6th ed).
- 520 http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfe
- 521 b1bc54639af227f922bf6b817.pdf. [accessed 6 June 2020].
- 522 27. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M et al. Effect of
- high vs low doses of chloroquine diphosphate as adjunctive therapy for patients
- hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- infection: A randomized clinical trial. JAMA Netw Open 2020;3(4):e208857.
- 526 https://doi.org/10.1001/jamanetworkopen.2020.8857.
- 527 28. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J et al. Clinical and
- microbiological effect of a combination of hydroxychloroguine and azithromycin in 80
- 529 COVID-19 patients with at least a six-day follow up: An observational study. Travel Med

- Infect Dis 2020;34:101663. https://doi.org/10.1016/j.tmaid.2020.101663.
- 29. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G et al. Observational study of
- hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med 2020;
- 7:NEJMoa2012410. https://doi.org/10.1056/NEJMoa2012410.
- 30. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L et al. A pilot study of hydroxychloroquine in
- treatment of patients with common coronavirus disease-19 (COVID-19). Zhejiang Da Xue
- Xue Bao Yi Xue Ban 2020;49(2):215–19. [in Chinese].
- 31. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan S et al. Efficacy of hydroxychloroguine in
- patients with COVID-19: Results of a randomized clinical trial.
- https://doi.org/10.1101/2020.03.22.20040758. [ahead of print].
- 32. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients
- with mainly mild to moderate coronavirus disease 2019: Open label, randomized
- controlled trial. BMJ 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.
- 33. Taiwan CDC. Interim guidelines for clinical management of SARS-CoV-2 infection (5th
- ed.), https://www.cdc.gov.tw/File/Get/-ewtg9-RCAetCPKR4 rnCw [accessed 6 June 2020].
- 34. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In vitro antiviral activity and
- 546 projection of optimized dosing design of hydroxychloroquine for the treatment of severe
- acute respiratory syndrome coronavirus 2(SARS-CoV-2). Clin Infect Dis 2020;ciaa237.
- 548 https://doi.org/10.1093/cid/ciaa237.





